Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Abbott Gains CE Marks For New Tricuspid Device And Expanded Xience DES Indication

Executive Summary

The next-generation TriClip G4 comes in more sizes than the original TriClip and features enhanced leaflet grasping features.

You may also be interested in...



Cardiovascular Catch-Up: J&J RF Balloon Ablation; Biotronik Home Monitor; And More

September has been full of cardiovascular technology news, including announcements from Biotronik and Biosense Webster. Here are a few of the highlights.

Abbott’s Q2 Medical Device And Diagnostic Sales Surpass 2019 Levels

Abbott expects the ongoing recovery of medical procedure volumes to continue even as new virus variants are causing COVID-19 cases to increase in some geographies.

FDA Approves Abbott Xience DES For Short Dual-Antiplatelet Course

The agency approved the Xience stents as suitable for patients at high bleeding-risk who can only stay on antiplatelet therapy for four weeks. Abbott also announced that it has received FDA approval and European CE mark approval for its Xience Skypoint stent.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

MT143762

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel